Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Novo Nordisk parent to acquire Catalent to shore up weight-loss drug production

The $16.5 billion deal is intended to provide manufacturing capability for drugs such as Wegovy

by Aayushi Pratap
February 9, 2024

Article:

This article has been sent to the following recipient: